速递｜药明康德炸裂财报里的另一条主线：GLP-1订单还在推高多肽制造景气

Core Insights - The core viewpoint of the article emphasizes that WuXi AppTec's recent financial performance is not just about revenue growth, but also highlights the emergence of peptide manufacturing as a new growth engine for the company driven by the GLP-1 drug trend [4][5]. Financial Performance - In 2025, WuXi AppTec achieved a revenue of 45.46 billion yuan, representing a year-on-year growth of 15.8%. The chemical business revenue reached 36.47 billion yuan, with a year-on-year increase of 25.5%. Notably, the TIDES business generated 11.37 billion yuan, marking a significant year-on-year increase of 96.0%, transitioning from a high-growth segment to a billion-level business [4]. GLP-1 Drug Impact - GLP-1 is identified as a crucial driving force behind WuXi AppTec's growth. The company is currently producing 23 GLP-1 drugs, with 16 in the II and III clinical trial phases. This indicates that WuXi AppTec is deeply embedded in the global core pipeline rather than being a passive beneficiary of the GLP-1 drug trend [4][5]. Industry Positioning - WuXi AppTec is not merely benefiting from "order dividends" but is actively moving up the industry chain. The high demands of GLP-1 drugs for peptide synthesis, scale-up production, quality control, and delivery capabilities mean that few companies can handle late-stage clinical and commercialization orders. By the end of 2025, WuXi AppTec's total volume of peptide solid-phase synthesis reactors exceeded 100,000 liters, indicating proactive capacity expansion to seize the global peptide manufacturing high ground [5]. Future Outlook - The article cautions against viewing GLP-1 as a perpetually high-growth single theme. As the base increases, order growth rates are expected to normalize, and the industry will shift from "capacity grabbing" to "delivery competition." However, WuXi AppTec's financial report demonstrates that GLP-1 is not only driving revenue but also facilitating the company's transition from a traditional R&D outsourcing leader to a core global peptide manufacturing platform [6].